Financials Jaguar Health, Inc.

Equities

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 12/07/2025 am IST			5-day change	1st Jan Change
2.700 ^USD	+2.66%		+4.65%	-89.31%

25/06	Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment	MT
11/06	Jaguar Health Establishes First Site for Canalevia-CA1 Field Study	MT

Projected Income Statement: Jaguar Health, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	9.385	4.335	11.96	-	11.69	12.56	26.55	28.18
Change	-	-53.81%	175.8%	-	-	7.42%	111.43%	6.16%
EBITDA ¹	-	-	-	-	-	-23.65	2.802	2.585
Change	-	-	-	-	-	-	111.85%	-7.74%
EBIT ¹	-26.65	-40.71	-34.42	-	-30.83	-25.55	-11.13	0.694
Change	-	-52.77%	15.46%	-	-	17.13%	56.44%	106.24%
Interest Paid ¹	-	-8.421	-12.72	-	-0.231	-2.4	-2.4	-
Earnings before Tax (EBT) ¹	-33.81	-52.6	-48.4	-	-39.25	-30.35	-14.68	-2.906
Change	-	-55.58%	7.99%	-	-	22.68%	51.63%	80.21%
Net income ¹	-38.65	-52.6	-47.45	-41.3	-38.49	-29.79	-14.4	-2.346
Change	-	-36.09%	9.77%	12.97%	6.8%	22.61%	51.66%	83.71%
Announcement Date	31/03/21	11/03/22	24/03/23	01/04/24	31/03/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q2	2020 Q3	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4
Net sales ¹	3.167	2.773	2.576	1.241	0.385	0.63	2.08	2.625	2.921	3.15	3.26	-	2.676	2.813	2.351	2.721	3.066	3.509	2.214	3.27	3.73	4.21	3.67	4.24	4.85	5.47
Change	-	-12.44%	-7.1%	-51.82%	-68.98%	63.64%	230.16%	26.2%	11.28%	7.84%	3.49%	-	-	5.12%	-16.42%	15.74%	12.68%	14.45%	-36.91%	47.7%	14.07%	12.87%	-12.83%	15.53%	14.39%	12.78%
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EBIT ¹	-4.755	-5.375	-	-8.766	-11.58	-9.529	-10.82	-11.75	-6.479	-9.896	-6.286	-	-8.102	-8.787	-8.215	-7.197	-7.262	-8.157	-9.421	-6.53	-6.51	-7.93	-5.51	-5.36	-5.27	-7.04
Change	-	-13.04%	-	-	-32.1%	17.71%	-13.57%	-8.61%	44.88%	-52.74%	36.48%	-	-	-8.45%	6.51%	12.39%	-0.9%	-12.32%	-15.5%	30.69%	0.31%	-21.81%	30.52%	2.72%	1.68%	-33.59%
Charge d'intérêts ¹	-0.479	-0.581	-	-	-2.009	-2.078	-2.433	-4.194	-2.536	-2.731	-2.634	-	-3.453	-0.5	-0.611	0.108	0.162	0.11	0.056	-0.6	-0.6	-0.6	-0.6	-0.6	-0.6	-0.6
Earnings before Tax (EBT) ¹	-9.238	-7.866	-	-12.01	-14.08	-12.19	-14.32	-18.16	-9.39	-12.61	-8.232	-	-12.29	-7.904	-9.368	-9.628	-10.02	-10.23	-10.6	-7.13	-7.11	-8.53	-6.11	-5.96	-5.87	-7.64
Change	-	14.85%	-	-	-17.25%	13.42%	-17.44%	-26.86%	48.3%	-34.28%	34.71%	-	-	35.69%	-18.52%	-2.78%	-4.08%	-2.13%	-3.54%	32.71%	0.28%	-19.97%	28.37%	2.45%	1.51%	-30.15%
Net income ¹	-10.6	-8.271	-	-12.01	-14.08	-12.19	-14.31	-17.99	-9.367	-12.52	-7.581	-12.2	-12.15	-7.778	-9.226	-9.492	-9.854	-9.92	-10.46	-7.13	-7.11	-8.53	-6.11	-5.96	-5.87	-7.64
Change	-	21.95%	-	-	-17.25%	13.42%	-17.4%	-25.66%	47.92%	-33.66%	39.45%	-60.96%	0.43%	35.98%	-18.62%	-2.88%	-3.81%	-0.67%	-5.48%	31.86%	0.28%	-19.97%	28.37%	2.45%	1.51%	-30.15%
Announcement Date	13/08/20	16/11/20	31/03/21	17/05/21	13/08/21	17/11/21	11/03/22	10/05/22	22/08/22	14/11/22	24/03/23	15/05/23	14/08/23	14/11/23	14/05/24	13/08/24	13/11/24	31/03/25	15/05/25	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Jaguar Health, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt ¹	-	-	-	-	-	-5	-5.59	-4.79
Change	-	-	-	-	-	-	-11.8%	14.31%
Announcement Date	31/03/21	11/03/22	24/03/23	01/04/24	31/03/25	-	-	-

¹USD in Million

Estimates

Cash Flow Forecast: Jaguar Health, Inc.

Fiscal Period: December	2021	2022	2024	2025	2026	2027
CAPEX ¹	0.006	0.077	0.016	0.1	0.1	0.15
Change	-	1,183.33%	-	525%	0%	50%
Free Cash Flow (FCF) ¹	-	-	-	-22.33	1.26	-0.125
Change	-	-	-	-	105.64%	-109.92%
Announcement Date	11/03/22	24/03/23	31/03/25	-	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Jaguar Health, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-	-	-	-	-	-188.37%	10.55%	9.17%
EBIT Margin (%)	-	-283.93%	-939.05%	-287.85%	-	-263.76%	-203.49%	-41.93%	2.46%
EBT Margin (%)	-	-360.25%	-1,213.38%	-404.78%	-	-335.79%	-241.72%	-55.3%	-10.31%
Net margin (%)	-	-411.81%	-1,213.26%	-396.91%	-	-329.3%	-237.26%	-54.24%	-8.32%
FCF margin (%)	-	-	-	-	-	-	-177.81%	4.75%	-0.44%
FCF / Net Income (%)	-	-	-	-	-	-	74.94%	-8.75%	5.33%
Profitability
ROA	-38.9%	-33.6%	-50.82%	-42.71%	-43.17%	-36.99%	-	-	-
ROE	-220.53%	-179.03%	-362.07%	-922.07%	-2,366.62%	-565.74%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	-	0.14%	0.64%	-	0.14%	0.8%	0.38%	0.53%
CAPEX / EBITDA (%)	-	-	-	-	-	-	-0.42%	3.57%	5.8%
CAPEX / FCF (%)	-	-	-	-	-	-	-0.45%	7.94%	-120%
Items per share
Cash flow per share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	1.73	1.47	1.66
Change	-	-	-	-	-	-	-	-15.03%	12.93%
EPS ¹	-	-3,37,500	-1,32,750	-54,270	-2,685	-130.7	-10.11	-3.125	-0.4
Change	-	-	60.67%	59.12%	95.05%	95.13%	92.26%	69.09%	87.2%
Nbr of stocks (in thousands)	-	0.31	0.41	1.34	33.8	472	1,324	1,324	1,324
Announcement Date	-	31/03/21	11/03/22	24/03/23	01/04/24	31/03/25	-	-	-